<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175200</url>
  </required_header>
  <id_info>
    <org_study_id>DOSAPI</org_study_id>
    <nct_id>NCT01175200</nct_id>
  </id_info>
  <brief_title>Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.</brief_title>
  <acronym>DOSAPI</acronym>
  <official_title>Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. A Prospective, Mono-center, Placebo- and Active Treatment-controlled, Randomized, Cross Over Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascopharm Groupe Novasco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medco Health Solutions, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ascopharm Groupe Novasco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will establish the optimal therapeutic strategy for patients with a coronary
      artery disease (CAD) and chronically treated with clopidogrel 75 mg/day requiring
      co-administration of an anti-platelet treatment with P2Y12 antagonist and a PPI for
      treatment/prevention of GI ulceration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in antiplatelet effect of clopidogrel</measure>
    <time_frame>14 days</time_frame>
    <description>change in antiplatetelet effect of clopidogrel as compared to prasugrel when associated to lansoprazole (or placebo) in patients with stable angina</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>high on-treatment platelet reactivity Clopidogrel pharmacokinetics responses</measure>
    <time_frame>14 days</time_frame>
    <description>compare persistant antiplatelet hyper reactivity in patients with stable angina and treated with clopidogrel or prasugrel associated with lansoprazole (or placebo)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Anti Platelet Effects</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>proton pump inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>antiplatelet agent</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>antiplatelet agent</description>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>proton pum inhibitor</description>
    <arm_group_label>Lansoprazole</arm_group_label>
    <other_name>Lanzor</other_name>
    <other_name>Ogast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo comparator similar to lansoprazole</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  patient with stable Coronary Artery Disease (&lt; 3 months) treated with clopidogrel
             (75mg/d)

          -  Between 18 and 75 years of age

          -  Body Mass Index between 18 and 30 kg/m2 and body weight not less than 60 kg

          -  No major bleeding according to ISTH definition

          -  Subjects who signed an informed consent document

          -  Subjects who signed a separate pharmacogenomic informed consent document

          -  Subjects registered to the French national welfare system

        Exclusion Criteria:

          -  Personal or family history of coagulation or bleeding disorders

          -  Use of known inhibitors or inducers of CYP2C19 and CYP3A including grape fruit juice
             intake

          -  Known hypersensitivity to lansoprazole, its excipients, or substituted benzimidazoles,

          -  Known hypersensitivity to clopidogrel / prasugrel

          -  Anti-platelet treatment other than clopidogrel + aspirin within 7 days before
             inclusion

          -  Any formal indication to maintain PPI treatment

          -  PPI within 15 days before inclusion in the study

          -  Active pathology with 10 days before inclusion

          -  Prior history of stent thrombosis

          -  Prior history of Stroke

          -  Employee of the investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that investigator or study center, as
             well as family members of the employees or the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pitié Salpétrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2010</study_first_posted>
  <last_update_submitted>July 3, 2012</last_update_submitted>
  <last_update_submitted_qc>July 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

